Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study



We aimed to gain insight into the real-world prevalence of potentially significant drug-drug interactions (DDIs) involving oral antineoplastic agents using nationwide data in Korea.


The data from the 2016 and 2017 Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS) of South Korea were used. The drugs prescribed concomitantly with oral anticancer drugs were screened for the potential DDIs by using two international DDI databases: LexicompTM and Micromedex®. Potentially significant DDIs were defined as DDIs with a severity rating of “major” or higher from at least one reference. The DDIs were classified into category 1 if the severity ratings were major or higher using both references.


Overall 5657 cases of DDIs in 2925 patients (26.4%) and 1640 cases of category 1 DDIs in 997 patients (9.0%) were identified among 11,076 patients receiving oral anticancer drugs. The prevalence was highest among the targeted agents (63.2%) followed by traditional (21.2%) and endocrine agents (19.3%). The common potential clinical consequences were increased risk of corrected QT interval prolongation (36.7%), reduced efficacy of antineoplastic agents (30.4%), and increased toxicities of antineoplastic agents (8.0%). Polypharmacy and the duration of oral cancer treatment increased the likelihood of potential DDIs in addition to individual antineoplastic agents.


This study showed that potentially significant DDIs with oral antineoplastic agents were prevalent in real-world practice. Recognizing the high prevalence of DDIs among patients taking oral antineoplastic agents is a necessary step toward improving the clinical outcome.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. 1.

    Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6(7):546–558.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H (2017) A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol 11(Suppl 5):87.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez-MacGregor M, Giordano SH, Johnson ML, Holmes HM (2019) Clinical outcomes associated with drug-drug interactions of oral chemotherapeutic agents: a comprehensive evidence-based literature review. Drugs Aging 36(4):341–354.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Herbrink M, Nuijen B, Schellens JH, Beijnen JH (2015) Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 41(5):412–422.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM (2019) Oral anticancer therapy: Management of drug interactions. J Oncol Pract 15(2):81–90.

  6. 6.

    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99(8):592–600.

    Article  PubMed  Google Scholar 

  7. 7.

    Vecchia S, Orlandi E, Confalonieri C, Damonti E, Riva A, Sartori A, Cavanna L (2018) Prevalence study on potential drug-drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department. J Oncol Pharm Pract 24(7):490–493.

    Article  PubMed  Google Scholar 

  8. 8.

    Ko Y, Tan S-LD, Chan A, Wong Y-P, Yong W-P, Ng RC-H, Lim S-W, Salim A (2012) Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 34(8):1696–1704.

    Article  PubMed  Google Scholar 

  9. 9.

    Andersson ML, Bottiger Y, Kockum H, Eiermann B (2018) High prevalence of drug-drug interactions in primary health care is caused by prescriptions from other healthcare units. Basic Clin Pharmacol Toxicol 122(5):512–516.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, Mehra N, van Erp NP (2018) Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. Br J Clin Pharmacol 84(1):122–129.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Armahizer MJ, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL (2013) Comparing drug-drug interaction severity ratings between bedside clinicians and proprietary databases. ISRN Crit Care 2013:1–6.

    Article  Google Scholar 

  12. 12.

    Solomon JM, Ajewole VB, Schneider AM, Sharma M, Bernicker EH (2018) Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract.

  13. 13.

    van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071–1078.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Gustafson E, Kettle J (2015) Analyzing trends in oral anticancer agents in an academic medical facility. J Hematol Oncol Pharm 5:34–37

    Google Scholar 

  15. 15.

    Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, Thavendiranathan P (2017) Incidence, diagnosis, and management of qt prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 6(12).

  16. 16.

    Keller KL, Franquiz MJ, Duffy AP, Trovato JA (2018) Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 24(2):110–115.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG (2014) Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15(8):e315–e326.

    Article  PubMed  Google Scholar 

  18. 18.

    Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer 115(11):1400–1407.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44–49.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Chan AJ, Rajakumar I (2014) High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract 20(2):93–99.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Shetty V, Chowta MN, Chowta KN, Shenoy A, Kamath A, Kamath P (2018) Evaluation of potential drug-drug interactions with medications prescribed to geriatric patients in a tertiary care hospital. J Aging Res 2018:5728957.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Wang W, Xiao B, Liu Z, Wang D, Zhu M (2019) The prevalence of the potential drug-drug interactions involving anticancer drugs in china: a retrospective study. Iran J Public Health 48(3):435–443

    PubMed  PubMed Central  Google Scholar 

Download references


This work was supported by Research Resettlement Fund for the new faculty of Seoul National University.

Author information



Corresponding author

Correspondence to Ju-Yeun Lee.

Ethics declarations

The protocol of this study was approved by the Seoul National University institutional review board (SNU 18-09-055).

Conflict of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The first two authors contribute equally and should be considered joint first author.

Electronic supplementary material


(PDF 349 kb).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, S.H., Suh, Y., Ah, YM. et al. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer 28, 3617–3626 (2020).

Download citation


  • Oral antineoplastic agents
  • Drug interaction
  • QTc prolongation
  • Polypharmacy